Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$442.2MCash, Jun 2026
57moCash Runway (est.)
Follow SPTX by emailGet an email when SPTX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SPTX, unsubscribe in one click. Privacy
📣 What SPTX Says Is Next
Second Half of 2026 · “Company Plans to Initiate a Phase 2a Proof-of-Pharmacology Trial in the Second Half of 2026.”
Company press release, Aug 3, 2026 · SEC filing
second half of 2026 · “Topline data from the driving simulation trial are expected in the second half of 2026, in advance of the expected topline readout of the BUOY-1 trial.”
Company press release, Aug 3, 2026 · SEC filing
2H 2026 · “Phase 1 Driving Simulation Trial in Healthy Volunteers is On Track - Topline data Expected in 2H 2026.”
Company press release, Aug 3, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
SPTX reported $442.2M in cash and short-term investments (as of Jun 30, 2026) and used about $23.3M/quarter in operations, an estimated runway of 56.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:8 · Low
Cash runway 57 months
S-1 registration (Apr 2026) +8
Recent financing filings on SEC EDGAR:
May 1, 2026 · Underwritten offering, $255M · 424B4
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SPTX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.